Switching From Semaglutide to Tirzepatide

If you are moving from semaglutide (Ozempic or Wegovy) to tirzepatide (Mounjaro or Zepbound) — usually for a stronger effect, better tolerability, cost, or supply reasons — the single most important thing to understand is counterintuitive: there is no dose-for-dose conversion between the two drugs. You do not "continue where you left off." You start tirzepatide at its lowest dose, 2.5 mg, no matter how high your semaglutide dose was. This article explains why, what the transition actually looks like, and what to expect for side effects.

Why there is no 1:1 conversion

Semaglutide and tirzepatide are different molecules with different receptor targets. Semaglutide activates only the GLP-1 receptor; tirzepatide is a dual agonist that activates both the GIP and the GLP-1 receptor¹. Because they are pharmacologically distinct, their milligram numbers are not interchangeable — 1 mg of semaglutide is not "equivalent" to any particular milligram of tirzepatide, and there is no validated equivalence table.

This shows up directly in the drug labels. Tirzepatide's FDA prescribing information sets a single recommended starting dosage — 2.5 mg injected subcutaneously once weekly for 4 weeks — and contains no provision for starting at a higher dose because a patient was previously on semaglutide². The same is true for the diabetes brand. There is simply no "switching from another GLP-1" shortcut written into the label.

So whatever you take away from this guide, take this: switching means restarting the titration ladder from the bottom.

You restart at 2.5 mg — and that is by design

The reason tirzepatide starts at 2.5 mg is not about weight-loss efficacy; the label is explicit that the 2.5 mg starting dose is for treatment initiation and is not intended as a maintenance dose. Its purpose is to let your gut adjust to the drug and reduce gastrointestinal side effects. After 4 weeks, the dose is increased to 5 mg, and from there it can rise in 2.5 mg increments after at least 4 weeks on the current dose, until you reach your maintenance dose².

That escalation logic does not care about your semaglutide history. Even someone coming off the top semaglutide dose (2.4 mg for Wegovy, 2.0 mg for Ozempic) begins tirzepatide at 2.5 mg and climbs the same ladder as a brand-new patient. The dose-escalation schedule exists to manage tolerability, and your gut has not "pre-adapted" to tirzepatide's GIP-plus-GLP-1 signaling just because it tolerated GLP-1 alone. (For the full ladder, see our tirzepatide dosage chart.)

Timing the switch

There is no special washout period mandated by the label, and switching is generally handled on the normal weekly cadence: because both drugs are once-weekly injections, the practical approach is to take your first 2.5 mg tirzepatide dose on the day your next weekly semaglutide dose would have been due — roughly a week after your last semaglutide injection. Tirzepatide's label requires at least 3 days (72 hours) between any two tirzepatide doses, so the weekly spacing is comfortably within bounds².

Because the label does not publish a formal switch protocol, the exact timing should be set by your prescriber, who can account for your last dose, your reason for switching, and your tolerability. This is a transition to plan with a clinician, not to improvise. (If you are weighing whether the switch is worth it at all, our head-to-head tirzepatide vs semaglutide breakdown covers what the comparative trials actually showed.)

Side effects re-titrate — expect the queasiness to return

Here is the part people most often underestimate. Even if your stomach had fully settled on semaglutide, expect gastrointestinal side effects to return as you climb tirzepatide's ladder. Nausea, diarrhea, vomiting, and constipation are the dominant side effects of tirzepatide; they are dose-dependent, most frequent during dose escalation, and the leading reason people stop the drug³. Starting low and stepping up slowly is exactly what blunts them².

In other words, switching resets the tolerability clock. You are starting a new drug at its lowest dose and re-titrating upward, so the early-titration nausea you may remember from your first weeks on semaglutide can recur on tirzepatide. This is normal and usually eases as each dose stabilizes; our guide to tirzepatide dosing and side effects covers how to manage it.

Will your results dip during the transition?

Possibly, briefly. Because you drop to a low tirzepatide dose for the first several weeks while you re-titrate, the appetite suppression and weight effect at 2.5 mg may feel weaker than your established semaglutide dose did. That is the expected trade-off of restarting the ladder, and it is temporary as you escalate. The pivotal trials show tirzepatide is a highly effective weight-loss drug at its maintenance doses, reaching roughly 21% mean body-weight reduction at 15 mg in the SURMOUNT-1 obesity trial⁴ — but that effect builds over the months of titration, not in the first weeks. Patience through the early low-dose phase is part of the plan.

The honest bottom line

Switching from semaglutide to tirzepatide is not a continuation; it is a restart. There is no 1:1 dose conversion because the two drugs are different molecules with different targets, so you begin tirzepatide at 2.5 mg regardless of your prior semaglutide dose, climb the same 4-week-step titration ladder everyone uses, and should expect gastrointestinal side effects to re-titrate along the way. Time the switch on the weekly cadence under your prescriber's guidance, and give the low starting dose time to escalate before judging the results. For the broader evidence on tirzepatide, see our tirzepatide evidence guide; and to compare access, providers, and pricing for the switch, start with our best tirzepatide overview.